Dayspring Pharma Announces Phase II Trial of CG2001 Foam Met Primary Endpoint in Chinese Adult Men with AGA ...Middle East

BEIJING, April 21, 2026 /PRNewswire/ -- Dayspring Pharma today announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful...

Hence then, the article about dayspring pharma announces phase ii trial of cg2001 foam met primary endpoint in chinese adult men with aga was published today ( Wednesday 22/04/2026 - 06:14 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Dayspring Pharma Announces Phase II Trial of CG2001 Foam Met Primary Endpoint in Chinese Adult Men with AGA )

Also on site :

• Water Bill Rate Hike Map: Where 300,000 Could Pay Hundreds More in Missouri
• The Evening News: Local Restaurant Owner Charged With Attempted Murder, UNC Faculty Committee Meeting
• U.S. Turns Up Pressure on Iraq to Distance Itself From Iran